Cargando…
Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8(+) progenitor exhausted T cell expansion in tumor models
CD8(+) exhausted T cells (T(ex)) are heterogeneous. PD-1 inhibitors reinvigorate progenitor T(ex), which subsequently differentiate into irresponsive terminal T(ex). The ability to maintain a capacity for durable proliferation of progenitor T(ex) is important, but the mechanism remains unclear. Here...
Autores principales: | Li, Xiang, Li, Yaru, Dong, Liang, Chang, Yixin, Zhang, Xingying, Wang, Chunmeng, Chen, Meixia, Bo, Xiaochen, Chen, Hebing, Han, Weidong, Nie, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065084/ https://www.ncbi.nlm.nih.gov/pubmed/36853831 http://dx.doi.org/10.1172/JCI165673 |
Ejemplares similares
-
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021) -
DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
por: Nie, Jing, et al.
Publicado: (2016) -
Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018) -
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021) -
Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation
por: Wang, Chunmeng, et al.
Publicado: (2023)